An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice.

Trial Profile

An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms LUDIC
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2012 Planned end date changed from 1 Apr 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 20 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top